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Abstract
Background:  Anti-cyclic citrullinated peptides (anti-CCP) are highly specific diagnostic and
prognostic markers for rheumatoid arthritis (RA). They have been also found in psoriatic arthritis
(PsA), with controversies as regards clinical and radiological associations. The current study
assessed anti-CCP in PsA and determined its clinical and radiological associations.
Methods: Four groups contributed to this study. 40 PsA, 40 psoriasis without arthritis, 40 RA and
40 healthy controls. They were tested for anti-CCP. Clinical and radiological data were collected
and statistically compared between anti-CCP-positive and -negative PsA patients.
Results: Seven PsA (17.5%) and 34 RA (85%) were seropositive for anti-CCP. Patients of other
groups were anti-CCP-negative. Regarding anti-CCP concentrations, highly significant difference
existed between different groups and between anti-CCP-positive and -negative PsA. Significantly
higher numbers of involved, swollen and tender joints, deformities and functional impairment of
peripheral joints and radiological changes were found in anti-CCP-positive PsA.
Conclusion: Anti-CCP may be found in PsA and are associated with higher number of involved,
swollen and tender joints, with deformities and functional impairment of peripheral joints and with
erosive arthritis.
Background
Psoriatic arthritis (PsA) is an inflammatory joint disease
that shares features of rheumatoid arthritis (RA). This
makes the differential diagnosis between PsA and RA in a
patient with psoriasis difficult [1,2]. Moreover, laboratory
test with specificity for PsA is still unavailable [1-3]. Vari-
ous classifications and diagnostic criteria for PsA have
been developed [4] of which the Moll and Wright [5] cri-
teria remain the simplest and the most frequently used
[4].
Antibodies targeting cyclic citrullinated peptide (anti-
CCP) have been detected in the serum of RA patients, with
high sensitivity and specificity [6-8] and serve as a power-
ful serologic marker for early diagnosis and prognostic
prediction of joint destruction and disease progression [9-
11]. Anti-CCP have been also identified in PsA with con-
troversies as regards its clinical and radiological associa-
tions [12-18]. The present study aimed to assess anti-CCP
in PsA and to determine its clinical and radiological asso-
ciations.
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Methods
Study design
This study represents a case-control study. Subjects were
randomly selected from those attending the outpatient
clinics of dermatology, rheumatology unit of internal
medicine and rheumatology and rehabilitation depart-
ments of Ain Shams University Hospitals, Cairo, Egypt in
the period from January 2006 to April 2008.
Study population
Four groups contributed to this study. Group I included
40 PsA patients. PsA was diagnosed based on Moll and
Wright criteria [5]. The presence of positive rheumatoid
factor (RF) was not considered an exclusion criterion [19].
Group II included 40 psoriatic patients without arthritis.
Group III included 40 RA patients diagnosed according to
the American Rheumatism Association (ARA) 1987
revised criteria [20] and group IV included 40 healthy vol-
unteers. Prior to initiation of the study, every subject was
informed about the aim of the study and gave consent.
All PsA patients were then subjected to:
a-Full history taking.
b-Dermatological examination including examination of
psoriatic nail changes and Psoriasis Area and Severity
Index (PASI) score [21].
c-Peripheral and axial joint evaluation according to Moll
and Wright criteria, modified by Helliwell et al [4]. Physi-
cal examination of joints included type and number of
joints involved, range of movement, number of swollen
and tender joints and presence of deformity or mutilating
arthritis. Oligoarthritis was considered when <5 joints
were involved and polyarthritis when ≥ 5 joints were
involved. Symmetric arthritis considered when bilateral
involvement >50% of affected joint was present.
d-Exclusion of RA using ARA 1987 revised criteria [20].
e-Plain radiographs of hands and feet and its evaluation
with emphasis on the presence of erosions, ankylosis,
cupping, whittling, deformities or destruction [4].
Blood sample was taken from all studied subjects. Serum
was extracted and frozen at -70°C until assayed for anti-
CCP and RF. Anti-CCP assay (cut-off, 5 U/ml) was done
using second generation ELISA (Axis Shield, Dundee,
UK). RF was assayed (cut-off, 15 IU/ml) using the com-
mercial ELISA (Sigma Diagnostics, St Louis, MO, USA).
HCV antibody was tested in RF-positive PsA patients using
third generation ELISA (ETI-AB-HCVK4, DiaSorin S.p.A.,
13040 Saluggia (Vercelli) – Italy).
Statistical analysis
Statistical analysis was carried out using the statistical
Package for the Social Sciences (SPSS) version 12. Quanti-
tative data were presented as mean, standard deviation
(SD), median and range while qualitative data were pre-
sented as number (n) and percentage (%). Differences
between continuous data were tested using Mann-Whit-
ney and Student's t-tests and differences between categor-
ical data were tested using Chi-square and Fisher's exact
tests. Analysis of variance (ANOVA) and Chi-square tests
were used to compare more than 2 groups as regards
quantitative and qualitative variables respectively. Post-
hoc tests were used for multiple comparisons between
groups. P-value ≤ 0.05 was considered statistically signifi-
cant and ≤ 0.001 highly significant.
Results
The study included 4 groups of studied subjects (table 1).
The first group included 40 patients with PsA; 18 males
and 22 females with mean age 42.85 ± 6 years. The second
group included 40 patients with psoriasis without arthri-
tis; 26 males and 14 females with mean age 43 ± 4 years.
The third group included 40 patients with RA; 9 males and
31 females with mean age 46.9 ± 5 years. The fourth group
included 40 healthy volunteers; 16 males and 24 females
with mean age 40 ± 4 years. No statistically significant dif-
ferences were found between different groups as regards
their age (P = 0.13).












Mean ± SD 42.85 ± 6 43 ± 4 46.9 ± 5 40 ± 4
Sex
Males n(%) 18(45%) 26 (65%) 9 (22.5%) 16 (40%)
Females n(%) 22 (55%) 14 (35%) 31 (77.5%) 24 (60%)
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Results of anti-CCP and RF in studied subjects
As regards anti-CCP, 7/40 PsA (17.5%) and 34/40 RA
patients (85%) were seropositive with respect to the cut-
off value. Patients with psoriasis without arthritis and
healthy controls showed anti-CCP concentrations below
cut-off value (anti-CCP-negative). On comparing the dif-
ferent groups together, statistically highly significant dif-
ference was found (table 2). As regards anti-CCP
concentrations (Figure 1), statistically highly significant
difference existed between the different studied groups
(table 3) as well as between anti-CCP-positive PsA, anti-
CCP-negative PsA, psoriasis without arthritis and healthy
controls (table 4). Post-hoc test revealed significant differ-
ences between PsA and psoriasis without arthritis (P =
0.012) and between PsA and healthy controls (P = 0.010).
Statistically highly significant differences were found
between RA and PsA, between RA and psoriasis without
arthritis, between RA and healthy controls and between
anti-CCP-positive and -negative PsA patients (P = 0.001).
On the other hand, no statistical difference was present
between anti-CCP-positive PsA and RA (P = 0.1464), and
between psoriasis without arthritis and healthy controls
(0.848).
As regards RF, seropositivity was found in 4 PsA patients
with respect to the cut-off value; 2 of them were also pos-
itive for anti-CCP. None of RF-positive PsA patients were
HCV-positive. All RA patients were RF-seropositive; 34 of
them showed anti-CCP seropositivity in addition. Two
psoriatic patients without arthritis and two healthy con-
trols were RF-positive. No statistical difference was found
between anti-CCP-positive and -negative PsA patients as
regards RF concentrations (P = 0.0714) (table 5).
Characteristics of anti-CCP-positive and-negative PsA 
patients
The demographic, clinical, laboratory and radiological
features of anti-CCP-positive and -negative PsA patients
are summarized in table 5. All PsA patients had psoriasis
vulgaris and arthritis. The arthritis was preceded by psoria-
sis in all patients, with mean ± SD: 22 ± 4 months. The
age, sex, disease duration and PASI score of anti-CCP-pos-
itive PsA were statistically insignificant from anti-CCP-
negative patients. Moreover, no statistical significance
existed between both groups as regards number of
patients with psoriatic nail changes, oligoarthritis or
spondyloarthritis. All patients with PsA and positive anti-
CCP had symmetric polyarthritis of peripheral small
joints. One of them had spondyloarthritis in addition.
Spondyloarthritis was more frequent in the anti-CCP-neg-
ative PsA patients (5/33). One patient had pure spondy-
loarthritis. In the other patients, spondyloarthritis was
present in addition to oligoarthritis (2/5) or polyarthritis
(2/5). None of the anti-CCP-positive or -negative patients
had arthritis mutilans. Statistically significant higher
numbers of involved, swollen and tender joints existed in
anti-CCP-positive PsA patients. Moreover, anti-CCP-posi-
tive patients had deformities and functional impairment
of peripheral joints, and radiological changes with statis-
tically significant difference from anti-CCP-negative
patients.
Bones and joints characteristics of anti-CCP-positive PsA 
patients
All anti-CCP-positive PsA patients had symmetric polyar-
thritis of peripheral small joints, limited range of move-
ment of interphalangeal joints and swan neck deformity
of distal interphalangeal joints, evident by both clinical
and radiological examination. They also showed periph-
eral boney erosions on radiographs. Ankylosis of different
interphalangeal joints was detected in 2 patients.













-negative n (%) 33 (82.5%) 40 (100%) 6 (15%) 40 (100%) <0.001
-positive n (%) 7 (17.5%) 0 34 (85%) 0
PsA: psoriatic arthritis, RA: rheumatoid arthritis
Mean anti-CCP concentrations of studied groups Figure 1
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Discussion
In the present study, anti-CCP were found in 17.5% of
PsA patients with significantly higher serum concentra-
tions from psoriasis without arthritis and healthy controls
and insignificant from RA. This adds further support to
previous studies [12-18] concerning the detection of anti-
CCP in PsA.
Significantly higher anti-CCP serum concentration, clini-
cal and radiological features were found in anti-CCP-pos-
itive PsA patients when compared with anti-CCP-negative
patients, suggesting the importance of anti-CCP testing in
PsA. Statistically significant higher numbers of involved,
swollen and tender joints were found in anti-CCP-positive
patients. Symmetric polyarthritis, limited range of move-
ment and deformities of small peripheral joints were also
present in the anti-CCP-positive PsA patients with statisti-
cally significant differences from anti-CCP-negative
patients. Anti-CCP seropositivity was also significantly
associated with radiological changes, manifested by
peripheral deformities and boney erosions. Similar results
have been widely reported in RA, and anti-CCP seroposi-
tivity has been shown to predict the future development
of joint destruction and disease progression [9-11].
In comparison with the previously published studies on
anti-CCP and PsA, our results agreed with some of these
studies [14-18], where anti-CCP seropositivity was associ-
ated with both clinical and radiological features. Other
studies on the other hand, revealed associations of anti-
CCP seropositivity only with polyarthritis [12,13]. Alen-
ius et al. [12] reported no associations with deformities,
functional impairment of peripheral joints or radiological
changes.
Based on the results obtained in our study, the key ques-
tion is whether these anti-CCP-positive patients truly have
PsA or whether in fact they represent patients who actually
have RA and psoriasis especially those with positive RF
and symmetric polyarthritis. The differentiation between
PsA and RA in patients with psoriasis is difficult [2]. The
Moll and Wright criteria [5] excluded RF positive patients
from a diagnosis of PsA. However, a false positive RF was
found in as many as 13% of patients with psoriasis and in
PsA as well [19]. Furthermore, RF seropositivity was found
in HCV related conditions [22] and in elderly patients
[23]. Regarding the 2 PsA patients with positive anti-CCP
and RF, one had 39 years and the second had 45 years and
they were HCV-negative. Using a higher cut-off value for
RF may increase specificity of RF testing and reduce the
number of false positive results. Further studies are how-
ever needed to clarify this suggestion.
Different reasons to favour PsA as the most likely diagno-
sis for these anti-CCP-positive patients were however
present. First, none of the patients fulfilled the ARA crite-
ria for RA. Second, all had arthritis and deformities of the
distal interphalangeal joints. Lastly, 4 out of the 7 patients
had psoriatic nail changes. The presence of higher number
of involved, swollen and tender peripheral small joints
and the associations with polyarthritis, functional impair-
ment and deformities of peripheral joints and erosive
arthritis may reflect the worse prognosis associated with
anti-CCP in PsA as the case in anti-CCP-positive RA.
Many authors [24,25] demonstrated the presence of anti-
CCP years before the clinical manifestation of RA. There-
fore, another hypothesis could be that anti-CCP-positive
PsA patients may suffer from an overlap with a preclinical
form of RA and in such cases anti-CCP testing help in
selection of patients who may need follow up, especially
with ARA criteria. Our study is expanded to clarify this
hypothesis, before putting a firm conclusion.














Mean ± SD 34.7 ± 8 3.21 ± 1.16 2.435 ± 1.3 2.68 ± 1.3 0.001
PsA: psoriatic arthritis, RA: rheumatoid arthritis












Mean ± SD 8.25 ± 11.6 2.435 ± 1.3 28.63 ± 11.75 2.68 ± 1.3 < 0.001
Median 3.8 2.5 32 1.8
PsA: psoriatic arthritis, RA: rheumatoid arthritisBMC Research Notes 2009, 2:44 http://www.biomedcentral.com/1756-0500/2/44
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Mean ± SD (range) 43 ± 5.7 (39–50) 47 ± 6.9 (33–54) 0.161*
Sex
Male n (%) 3 (42.86%) 15 (45.45%)
female n (%) 4 (57.14%) 18 (54.55%) 0.67**
Disease Duration (months)
Mean ± SD (range) 40.7 ± 12.34 (30–54) 37 ± 9 (24–60) 0.36*
PASI
Mean ± SD (range) 10 ± 1.53 (8–11) 8.86 ± 1.9 (7–13) 0.146*
Psoriatic nail changes
n (%) 4 (57.14%) 29 (87.9%) 0.087**
Involved joints
median (range) 15 (10–24) 6 (5–10) 0.0135*
Swollen joints
median (range) 2.5 (2–7) 1 (0–2) 0.023*
Tender joints
median (range) 9 (3–16) 3 (0–8) 0.009*
Spondyloarthritis
n (%) 1 (14.28%) 5 (15.15%) 0.901**
Oligoarthritis
n (%) 0 6 (18.18%) 0.567**
Symmetric Polyarthritis
n (%) 7 (100%) 12 (36.36%) 0.003**
Asymmetric Polyarthritis
n (%) 0 2 (6.06%) 0.542**
Deformities of peripheral joints
n (%) 7 (100%) 15 (45.45%) 0.011**
Functional impairment of peripheral joints
n (%) 7 (100%) 15 (45.45%) 0.011**
Radiological changes:
peripheral deformities/erosions
n (%) 7 (100%) 15 (45.45%) 0.011**
RF concentrations (IU/ml)
Median (range) 15 (7–30) 9 (4–33) 0.0714*
Anti-CCP concentrations (U/ml)
Mean ± SD (range)
34.7 ± 8 (30–45) 3.21 ± 1.16 (1–5) 0.0001*
* Student's t and Mann Whitney tests.
** Chi-square and Fisher's exact testsBMC Research Notes 2009, 2:44 http://www.biomedcentral.com/1756-0500/2/44
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Even if the definite diagnosis remained in doubt, the evi-
dence presented here suggests that as in RA, any patient
with PsA and positive anti-CCP falls into a special cate-
gory. Anti-CCP may be a marker for, or contribute to dis-
ease severity. It may be also one factor that influences
treatment selection and response. Early treatment with
disease modifying anti-rheumatic drugs (DMARD)
whether conventional drugs as methotrexate or biological
agents may prevent the progression of joint damage since
no available treatment can reverse significant joint dam-
age [26]. Prospective studies are warranted in this clinical
setting. In RA, anti-CD20 monoclonal antibody (rituxi-
mab) has been shown to reduce circulating levels of anti-
CCP [27].
Conclusion
Although the number of anti-CCP-positive PsA in the
present study was relatively small, yet the significant dif-
ferences found in its serum concentrations between the
studied groups help us to draw conclusions. Anti-CCP-
seropositivity in PsA is associated with several clinical and
radiological features and therefore, it may be considered a
marker of, or contributes to disease severity. However, this
study has to be expanded and focused on a large group of
PsA to confirm any true association or future evolution of
anti-CCP-positive patients to RA, before putting firm con-
clusions.
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